Intensity Therapeutics’ INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas
Compared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered Cytotoxic Treatment Leading to a Systemic Immune Response in Hot or Cold Tumors, Is A New Way To Treat Sarcoma…
Comments Off on Intensity Therapeutics’ INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult Patients with Relapsed, Refractory, Metastatic Sarcomas